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ABSTRACT
If the defi nition of eliminating of a health disparity were signifi ed by the absence 
of any diff erences in incidence or mortality between a population’s experiences with a 
health problem, then the only health disparity that has ever been eliminated is smallpox 
because with zero cases of smallpox in the world, no health disparities exist because 
of smallpox.  The eradication of smallpox is perhaps the only historical example where 
the elimination of a health disparity has been achieved.  Principles and lessons learned, 
particularly through the intersection of science and policy that could be applied to 
the elimination of other health disparities both domestically and internationally are 
proposed.
Key Words:  Health disparities; Liver Cancer
INTRODUCTION
Pursuing a National Policy for Preventing Hepatitis B-induced Liver Cancer:
Implications for Eliminating Health Disparities 
As stated in Healthy People 2010, one of our national goals is “to eliminate health disparities” 
(US Department of Health and Human Services [DHHS], 2000). Operationalizing this goal has 
yielded many defi nitions of health disparities (Carter-Pokras, Baquet, 2002; DHHS, 2004), including 
a legal defi nition of a “health disparity population” as being mutually determined by the Director 
of the National Center on Minority Health and Health Disparities and the Director of the Agency for 
Healthcare Research and Quality based on the presence of a “signifi cant disparity in the overall rate of 
disease incidence, prevalence, morbidity, mortality, or survival rates in the population as compared 
to the health status of the general population” (Public Law 106-525, 2000).  Examples of health 
disparities abound between and among population groups in the US (DHHS, 1985; Haynes, Smedley, 
1999; Smedley, Stith, Nelson, 2003; Williams, Jackson, 2005; Kawachi, Daniels, Robinson, 2005; 
Satcher, Fryer, McCann, 2005; Lurie, 2005; Miller, Chu, Hankey, Ries, 2007) and various methods have 
been proposed to measure health disparities (Harper, Lynch, 2005, National Research Council, 2005)   
Despite these eff orts, there is a paucity of examples of health disparities that have been eliminated.
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  If the elimination of a health disparity were signifi ed by the absence of any diff erences in 
incidence or mortality between any population’s experience with a health problem or disease, then 
the only health disparity that has ever been eliminated was smallpox in 1980 (Fenner, Henderson, 
Arita, Jezek, Ladnyi, 1988).  Smallpox is the fi rst disease that the World Health Organization has ever 
certifi ed as being “eradicated”, i.e., “reduction of the worldwide incidence of a disease to zero as a 
result of deliberate eff orts, obviating the necessity for further control measures” (Recommendations 
of the International Task Force for Disease Eradication, 1993; Henderson, 1999) and thus, no 
disparities exist.   Thus, pursuing a national policy to eliminate health disparities should consider the 
example of smallpox.
“Disparities” are not simply “diff erences” in health status (Adler, 2006; Braveman & Gruskin, 
2003).   Rather, in our context, disparities are diff erences that may be attributable to potentially 
amenable socio-cultural and socioeconomic factors (DHHS, 2000).  (Diff erences related to immutable 
factors, e.g., inherited attributes are not disparities.)  Eliminating health disparities must transcend 
eliminating barriers to health care since even the adoption and implementation of the Institute 
of Medicine’s Unequal Treatment (Smedley, Stith, Nelson, 2003) would be principally contributing 
to the reduction of health care disparities, not their absolute elimination (Adler, 2006). With the 
elimination of smallpox as a health disparity condition as the model, the purposes of this paper are as 
follows:  (1) justify the focus of hepatitis B-related liver cancer and its parallels with smallpox as a next 
opportunity for eliminating health disparities both on a national and a global basis; (2) recommend 
policies that would advance the elimination of health disparities; and (3) distill principles that appear 
to be key factors in eliminating health disparities.
Rationale for the focus on hepatitis B-related liver cancer and its parallels with smallpox
We chose to focus on hepatitis B-related liver cancer as the example for this paper for three major 
reasons:  
(1) The hepatitis B virus (HBV) is a documented human carcinogen.
(2) HBV-induced liver cancer is a documented health disparity for U.S. racial/ethnic 
minority populations.  
(3) HBV-related liver cancer mortality is preventable and can potentially be eliminated as a 
cause of death and disparities.
Hepatitis B virus as a human carcinogen
First, the hepatitis B virus (HBV) is a documented human carcinogen.  In 2004, the U.S. 
Department of Health and Human Services Report on Carcinogens listed the HBV and the hepatitis 
C virus (HCV) as substances known to be human carcinogens, making them the fi rst viruses declared 
to be etiologically related to hepatocellular carcinoma (HCC) (DHHS, 2004) and is responsible for 
about 90% of the cases (London, McGlynn, 2006).  In fact, one-third of the world’s population or two 
billion people are infected with HBV (World Health Organization [WHO], 2004) and at least 350 to 400 
million (6% of world’s population) are chronically infected as carriers (WHO, 2004; Ocama, Opio, Lee, 
2005), making it among the most common infections in the world and responsible for HCC being the 
third leading cause of cancer mortality in the world (Parkin, 2001).  Second to tobacco use, the most 
preventable cause of cancer is infection (Kuper, Adami, 2000), and because of tobacco and infections, 
cancer is expected to become the world’s leading cause of death in 2010 (International Agency on 
Research in Cancer, 2008).
Disparities associated with HBV in U.S. racial/ethnic minority populations 
While the incidence and mortality rates for the great majority of cancer sites in the U.S. have been 
steadily decreasing, liver cancer is one of the few cancer sites with increases in incidence (second 
highest among all cancer sites) and mortality (highest among all cancer sites) (Jemal, Siegal, Ward, 
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Xu, Thun, 2008).  Between 2001-2005 the annual percentage change in male liver cancer incidence 
was 3.3 compared to a decrease of 3.2 for larynx cancer; the annual percentage change in liver 
cancer mortality was 2.1 compared to a decrease of 4.1 for prostate cancer.  Among females, liver 
cancer incidence rose by 1.3 annually compared to a decrease of 3.7 for cervical cancer; the annual 
percentage change in liver cancer mortality was 1.1 compared to a decrease of 3.4 for cervical cancer. 
Increases in liver cancer may be attributable in great part to increasing infections by HBV and HCV 
and these increases have been disproportionally aff ecting all people of color (Jemal, Siegl, Ward, et 
al., 2008). 
Figures 1 (incidence) and 2 (mortality) graphically depict how the rates of HCC for each 
U.S. racial/ethnic minority population are all greater than those of Whites.  Not shown in these 
graphs are analyses that indicate age-adjusted HCC incidence rates tripled with notable increases 
among Hispanic, Black, and White men between 1975 to 2005.  At the same time, incidence rates 
are increasing with each successive birth cohort between 1900 and 1959 (Alterkruse, McGlynn, 
Reichman, 2009).   
Un fortunately, survival rates for liver cancer rank the second worst among all cancer sites.  
For liver cancer, the survival rate for Whites is only 10% but the survival rate for Blacks is lower, 
7%.  Racially-specifi c fi ve-year survival rates from the National Cancer Institute’s Surveillance 
Epidemiology and End Results Program are not available for other populations (Jermal, Siegel, Ward, 
et al., 2008).  Clearly, HBV-induced liver cancer qualifi es as a signifi cant cancer health disparity for all 
U.S. racial/ethnic minority populations and is the most signifi cant cancer health disparity aff ecting 
Asian Americans (Chen, 2005).
Potential for eliminating HBV-related liver cancer as a cause of death and disparities
   With the exception of the strains of cervical cancer that could be prevented by new vaccines 
(Markowitz et al., 2007; Saslow et al., 2007), preventing hepatitis B-induced infections cancer off ers 
us the potential for virtually eliminating transmission of this virus for the next generation. In fact, the 
American Cancer Society declared that the hepatitis B vaccine was the world’s fi rst eff ective “anti-
cancer” vaccine (American Cancer Society, 2001; Aoki, Geller, Chen, 2009, p. 227-56).
The most cost-eff ective means of preventing HBV-related liver cancer and its precursor, 
chronic HBV infection, for those who never have been infected is by vaccination (Zanett, Van Damme, 
Shouval, 2008).  Studies in Taiwan have demonstrated the eff ectiveness of HBV vaccination in 
reducing hepatitis B surface antigen positivity, the principal indicator of infection (Chang et al., 1997) 
and HBV carrier rates (Lee, 1997).   Subsequently, the eff ectiveness of the HBV vaccination eff orts in 
Taiwan have been documented by decreasing prevalence of the hepatitis B surface antigen positivity 
rates by birth cohort (Su et al., 2007; Ni et al., 2007)  
In the United States, most states have instituted universal HBV vaccination of infants and 
requirements for HBV vaccination for school entry for older children.  Thus, in the future, HBV 
vaccinations may eventually protect subsequent generations of youth from HBV infection (Aoki, 
Gella, Chen, 2009, p. 227-56).  
However, vaccination does not protect those already infected with HBV; vaccination without 
serological testing would potentially miss many who are already infected providing a false sense 
of protection.  An estimated two million people in the United States are chronically infected with 
HBV (Cohen, Evans, London, 2008), a large proportion of whom are unaware of their infection (Aoki, 
Gellar, Chen, 2009, p.227-56; Lin, Chang, So, 2007) and hence not under medical care.  Despite the 
best intentions, serologic testing for HBV infection among Asian American adults is under-utilized 
(Nguyen, et al., 2007; Chang, et al., 2007). 
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Figure 1. Age-adjusted HCC Incidence Rates Based on Diagnoses in 2003-2005 among U.S. 
Racial/Ethnic Populations.
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Figure 2. Age-adjusted HCC Mortality Rates Based on Diagnoses in 2003-2005 among U.S. 
Racial/Ethnic Populations.
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Recommendations for policies to eliminate hepatitis B-induced liver cancer
Based on the rationale presented above, we propose a three-tiered U.S. national policy that 
emphasizes primary prevention of HBV infections---i.e., measures intended to avoid infection; 
secondary prevention---screening for those considered to be at high-risk for HBV-induced liver 
cancer; and tertiary prevention---aggressive treatment of those who have been infected to improve 
their quality of life and to reduce transmission to others.  In some respects, these three tiers are 
already operational; however, we have not articulated a clear national policy that links these tiers 
together synergistically. 
Primary Prevention
Prevention of HBV infections through vaccination had its origins through pioneering 
epidemiological studies by Beasley (1982; 1988) documenting the etiological relationships between 
HBV infections and hepatocellular carcinoma, followed by the initiation of the world’s fi rst nationwide 
HBV vaccination program in Taiwan, fi rst for infants born to hepatitis B surface antigen carrier 
mothers in 1984 and subsequently to all infants in 1986 (Chang, et al., 1997; Chen, et al., 1987).  Two 
decades after nation-wide implementation of universal birth-dose HBV vaccination, Taiwan has 
seen dramatic reductions in seropositive rates for hepatitis B surface antigens and other markers of 
HBV infections and increases in immunity against HBV.  These indicators of reduced HBV infections 
have been consistent with the longitudinal tracking of the same birth cohorts in surveys previously 
conducted in 1984, 1989, 1994, and 1999 (Ni, et al., 2007).  Primary prevention prior to their onset 
through HBV vaccinations is unquestionably the most preferred, most eff ective (Chang, et al., 1997; 
Ni et al., 2007; Chen et al., 1987; Poland, Jacobson, 2004; Chen et al., 2004; Chang et al., 2005) and 
the most cost-eff ective approach (Margolis et al., 1995; Zhou et al., 2003; Fontham, 2009; Lang, 
Danchenko, Gondek, Shah, Thompson, 2009).  The estimate of the fi nancial burden of hepatocellular 
carcinoma in the United States is $32,907 per patient or $454.9 million.  Hence, interventions 
to reduce the prevalence of hepatocellular carcinoma would be economically benefi cial (Lang, 
Danchenko, Gondek, Shah, Thompson, 2009).  
The incidence of HBV transmission has declined due to the adoption of a Centers for Disease 
Control and Prevention recommended comprehensive strategy (Centers for Disease Control and 
Prevention [CDC], 1991; 2002; 2004; Weinbaum, et al., 2008).  For example, data from Hawaii, the 
state with the largest proportion of at-risk Asian Pacifi c Islanders, exemplify the eff ectiveness of the 
fi rst three of CDC’s recommended strategies among elementary school-aged children (Dilraj et al., 
2003; Perez et al., 2006),  namely, 1) Universal vaccination of infants beginning at birth; 2) prevention 
of perinatal HBV infection through routine screening of all pregnant women for HBV infection and 
provision of immunoprophylaxis to infants born to infected women or to women of unknown 
infection status; 3) routine vaccination of previously unvaccinated children and adolescents.  The 
adoption of these three strategies has been facilitated by professional endorsement from various 
organizations such as the ACIP and the passage of various state laws requiring evidence of HBV 
vaccination as prerequisites for school entry and the provision of free or low-cost HBV vaccinations 
through the Federally subsidized Vaccines for Children’s program.  
Secondary prevention of hepatitis B infections
However, HBV continues to be an important cause of mortality, particularly among foreign-born 
residents (Kim et al., 2004) with attribution also to horizontal transmission (Franks et al., 1989).   For 
these adults, secondary prevention or early detection and screening is highly recommended because 
early detection of HCC improves survival and alerts family members and friends to screening. Patients 
with HCC diagnosed at an early stage who are able to undergo liver transplant or resection have a 
fi ve year mortality rate of 60%.  While those who have been diagnosed with HCC diagnosed at a late 
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stage, their survival rate is less than 10%.  Due to the improved survival with early detection, the 
American Association for the Study of Liver Disease (AASLD) produced guidelines of the patients and 
methods of screening for liver cancer (Lok, McMahon, 2007). The AASLD recommends screening for 
HCC, by testing an alpha-fetoprotein (AFP) and abdominal ultrasound every 6 to 12 months, among 
HBV carriers who were born in Asia, starting at age 40 in men and women starting at age 50. This is 
based on prospective data from Asia that showed that among HBV carriers the risks of developing 
HCC increases to 0.2% per year starting at age 40 in men.  In addition to age, HBV carriers who have 
a family history of HCC are at a high risk of developing HCC (Yu et al., 2000) and thus anyone with a 
family history of HCC should also be screened for HCC regardless of development of cirrhosis, though 
the age at which this should start is unknown. HBV carriers born in Africa, also appear to have a high 
risk of HCC which can occur at a young age. Therefore the AASLD recommends screening at age 20 
in this group (Kew, Macerollo, 1988). Finally anyone with cirrhosis due to HBV should be screened 
for HCC as these patients have a 2.5% annual incidence of HCC (Velazquez et al., 2003).  Controversy 
regarding these guidelines has been seen in the U.S., largely because HBV induced HCC is a relatively 
small contributor to the rise in HCC in the U.S. In Asia, where hepatitis B is the main contributor to 
HCC, screening using AFP and abdominal ultrasound has been shown to be benefi cial to reducing 
mortality from HCC. This has been shown in numerous retrospective studies, and one randomized 
controlled trial showed that despite only 60% adherence, the surveillance group had a 37% reduction 
in mortality compared to the control group (Zhang, Yang, Tang, 2004).  Thus it is important that 
adults born in HBV endemic areas, such as Africa or Asia, need to be tested for the hepatitis B surface 
antigen before vaccination to determine if they are chronic carriers.     
Tertiary prevention 
Unfortunately, tertiary prevention, i.e., aggressive treatment of those who have been infected to 
avoid relapse or death, lags far behind the state-of-the-science in primary prevention and secondary 
prevention.  While there have been promising treatments (Dienstag, 2008) and liver transplants that 
have prolonged survival (Lok, McMahon, 2007; Taketomi et al., 2008), the prognosis for hepatitis 
B-induced liver cancer patients remains dismal.  Certainly, increased funding for research should be a 
part of our national policy.  In the meanwhile, a national policy that continues to emphasize primary 
prevention (vaccination) and secondary prevention (early detection of HBV) are key.  
At the same time, we recognize that simply increasing HBV vaccination and early detection 
eff orts will not entirely eliminate the occurrence of liver cancer.  HCC may also be attributable to HCV 
infections for which no vaccination exist and to other risk factors or conditions such as tobacco use 
(Chen, Yu, Liaw, 1997), being overweight (Calle, Rodriguez, Walker-Thurmond, Thun, 2003; Cadwell, 
Crespo, Kang, Al-Osaimi, 2004), alcohol abuse (Chen et al., 1991), diabetes (Davida, Morgan, Shib, 
McGlynn, El-Serag, 2005; El-Serag, Hampel, Javadi, 2006), afl atotoxin consumption (Qian, et al., 1994), 
and other factors, both behavioral and environmental (Yu, Yuan, 2004). Unquestionably, each of 
these factors being both behavioral or environmental in origin are much more diffi  cult to alter.  By 
contrast, primary and secondary prevention of HBV are relatively easier to implement.  Preventing 
HBV infections and treating those infections should eventually eliminate HBV as a causative agent 
and signifi cant reduce rates of HCC.
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CONCLUSION
Lessons learned and principles for eliminating health disparities
Using the example of smallpox as a model, we derived the factors displayed in Table 1 that 
contribute to elimination of a health disparity.  With respect to a disease worth the eff ort, we 
postulate that just as smallpox was a highly prevalent and devastating disease worthy of sparing 
humanity, so is HBV-induced liver cancer for the same reasons.  The elimination of hepatitis B-induced 
liver cancer through prevention (vaccination), early detection, and treatment is a most worthwhile 
national policy and priority.  Eliminating hepatitis B-induced liver cancer is feasible; eliminating this 
known carcinogen through prevention and earlier detection will save lives and money.      
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